What are the methods for treating malignant pleural effusion of lung cancer? Malignant pleural effusion of lung cancer can be treated like this

The main methods for treating malignant pleural effusion of lung cancer include systemic chemotherapy, thoracentesis and pleural adhesion. Among them, systemic chemotherapy can be divided into two forms: external thoracic irradiation and intrathoracic irradiation. After the rational use of external thoracic irradiation treatment, the effective rate can reach 70%. Since it is difficult to recover the discharge of internal thoracic irradiation, it is not widely used. In addition, thoracentesis and pleural adhesion have relatively good therapeutic effects and can be used according to the specific symptoms of the patient.

Malignant pleural effusion often occurs in the late stage of lung cancer, and the probability of occurrence is relatively high, reaching about 60%. According to clinical medical practice research, the main reason for the formation of malignant pleural effusion is that the metastatic nodules of the pleura stimulate and block the capillaries and lymphatic vessels. Therefore, a large amount of visible blood components and proteins can be found in the pleural effusion. Since this disease causes serious damage to the patient, it should be treated without delay.

Normally, systemic chemotherapy can be used to curb the development of malignant pleural effusion. Among them, radiotherapy for malignant pleural effusion includes two methods, one is external thoracic irradiation and the other is intrathoracic irradiation. Since external thoracic irradiation can relieve the obstruction of lymphatic vessels and thoracic ducts during the entire radiotherapy process, if it is a sensitive malignant tumor, the effectiveness rate can reach about 70% after external thoracic irradiation treatment.

If the external thoracic irradiation is not performed, but the method of internal thoracic irradiation is used to treat malignant pleural effusion, a relatively ideal treatment effect can also be achieved. During the internal thoracic irradiation, isotope phosphorus is injected into the inner side of the thoracic cavity, which can reduce malignant pleural effusion by about 59%. However, due to many factors such as the difficulty in collecting radioactive discharge, it has not been widely used at present.

In addition, if after a comprehensive examination of the patient, it is found that the patient is not suitable for systemic chemotherapy, thoracentesis can also be considered. Thoracentesis can extract part or even all of the pleural effusion, which will have a good short-term relief effect on the symptoms of dyspnea and can greatly reduce the adverse conditions of critically ill patients. It is a relatively good treatment method.

In addition to the above two methods for treating malignant pleural effusion, pleural adhesion can also be used for treatment according to the patient's specific symptoms. Pleural adhesion is a more reliable treatment method among many treatment methods, and it causes less trauma to patients. It can inject a hardener into the chest cavity, and by stimulating the visceral and parietal pleura, it can improve the structure of the mesothelial tissue and gradually make it fibrotic, thereby increasing the adhesion of the two layers of pleura, relieving dyspnea and eliminating pleural effusion.

Finally, patients should be reminded that whether it is systemic chemotherapy, thoracentesis, or pleural adhesion surgery, they all need to be carefully examined and diagnosed by professional doctors, and scientifically selected according to the specific physical condition and disease conditions of patients with malignant pleural effusion. For the sake of their own health, patients are advised to pay more attention to it. Once such a disease is found, it should be treated in time so as to recover health as soon as possible.